To provide the German location of biotechnology and pharma industry with fresh impulsion, the German Federal Ministry for Education and Research (BMBF) started the pharma initiative "BioPharma: The Strategy Competition for Future Medicines". The Neuroallianz Consortium was nominated for this initiative.
The Neuroallianz Consortium has created a novel strategic partnership where various academic institutions and companies are working jointly on innovative diagnostic and therapeutic research projects. The aim is to efficiently transform research into benefits for the patients.
Main focuses are diagnostic and therapy of neurodegenerative diseases such as Parkinson's Disease, or Alzheimer's Dementia, and Epilepsy.
Duration: 2009 – 2018
Budget: 40 Mio. €